Diki Arma Duha, Edward Usfie Harahap, Rachmat Budi Santoso, I. A. Bramono
Background: Kidney cancer is one of the most prevalent cancers in urology. The higher prevalence of risk factors, as well as better diagnostic modalities, has led to a reported increase worldwide. The study aims to describe the profile and management pattern of kidney cancer patients at a tertiary referral center over seven years.Methods: A descriptive study was conducted to assess the profile and management of kidney patients in the national cancer center (NCC) - Dharmais Hospital Jakarta between January 2013 and December 2020. The variables collected included age, gender, stage (AJCC staging), histopathological result, and management, using the total sampling method.Results: A total of 53 kidney cancer cases were documented in NCC - Dharmais Hospital Jakarta from 2013 to 2020. Overall, males are more prevalent than females, with a sex ratio of 2.3:1. The most frequent age group was 51–65 years. The most common histological subtype was a clear cell in the renal cell carcinoma (RCC) subtype and sarcoma in the non-RCC subtype. Noticeably, end-stage (stage IV) was found in more than half of patients (65.6%), with no patient found in stage I. Radical nephrectomy was preferable to cytoreductive nephrectomy. Conclusions: : An increasing trend of kidney cancer incidence was found between 2013 and 2020 with most patients diagnosed with stage IV.
{"title":"Kidney Cancer Profile in National Cancer Center (NCC) - Dharmais Cancer Hospital","authors":"Diki Arma Duha, Edward Usfie Harahap, Rachmat Budi Santoso, I. A. Bramono","doi":"10.33371/ijoc.v16i4.904","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.904","url":null,"abstract":"Background: Kidney cancer is one of the most prevalent cancers in urology. The higher prevalence of risk factors, as well as better diagnostic modalities, has led to a reported increase worldwide. The study aims to describe the profile and management pattern of kidney cancer patients at a tertiary referral center over seven years.Methods: A descriptive study was conducted to assess the profile and management of kidney patients in the national cancer center (NCC) - Dharmais Hospital Jakarta between January 2013 and December 2020. The variables collected included age, gender, stage (AJCC staging), histopathological result, and management, using the total sampling method.Results: A total of 53 kidney cancer cases were documented in NCC - Dharmais Hospital Jakarta from 2013 to 2020. Overall, males are more prevalent than females, with a sex ratio of 2.3:1. The most frequent age group was 51–65 years. The most common histological subtype was a clear cell in the renal cell carcinoma (RCC) subtype and sarcoma in the non-RCC subtype. Noticeably, end-stage (stage IV) was found in more than half of patients (65.6%), with no patient found in stage I. Radical nephrectomy was preferable to cytoreductive nephrectomy. Conclusions: : An increasing trend of kidney cancer incidence was found between 2013 and 2020 with most patients diagnosed with stage IV.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78086706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ester Marsaulina Marsaulina, R. Andrajati, Yuri Pertamasari, Alvinda Heriza Nasution
Background: Anthracycline is the first-choice chemotherapy for the treatment of breast cancer, particularly in elderly patients. However, several studies reported adverse events in the treatment of using anthracyclines. This study aims to identify adverse events. It is also to find out more about how independent variables are related to adverse events. Method: An observational retrospective study of elderly patients (≥ 60 years old) was conducted in a tertiary cancer hospital in Jakarta. Data were collected from January 2018 to December 2020. We used an oncology-specific trigger tool to identify adverse events during anthracycline-based regimens. Independent variables were evaluated in univariate analysis: age, weight loss, marital status, total cumulative dose, polypharmacy, types of anthracyclines, and metastatic status. Bivariate and multivariate analyses were conducted to find out the relationship between the independent variables and adverse events.Results: In total, 107 subject records were collected and reviewed. Triggers were identified 122 times in 86 medical records. Blood transfusion, the most common trigger, was found in 35% of subjects. We found the number of triggers and adverse events more commonly identified in the first and second cycles of chemotherapy. The prevalence of adverse events is detected in 80% of subjects. Of these 86 subjects, 74% were detected in doxorubicin and 26% were detected in epirubicin. All the adverse events were categorized as The National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) harm category E.Conclusion: Trigger tools specific for cancer patients can be used to identify adverse events. Blood transfusion was the common trigger to detect adverse events in our study. Adverse events with category E were identified in all the subjects. Neutropenia and anemia were the most common adverse events in all cycles of chemotherapy. Weight loss was the independent variable related to adverse events in elderly breast cancer patients (p <0.003).
{"title":"The Identification and Analysis of Adverse Events in Elderly Female Breast Cancer Patients Using Anthracycline-Based Regimens at Dharmais Cancer Hospital","authors":"Ester Marsaulina Marsaulina, R. Andrajati, Yuri Pertamasari, Alvinda Heriza Nasution","doi":"10.33371/ijoc.v16i4.898","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.898","url":null,"abstract":"Background: Anthracycline is the first-choice chemotherapy for the treatment of breast cancer, particularly in elderly patients. However, several studies reported adverse events in the treatment of using anthracyclines. This study aims to identify adverse events. It is also to find out more about how independent variables are related to adverse events. Method: An observational retrospective study of elderly patients (≥ 60 years old) was conducted in a tertiary cancer hospital in Jakarta. Data were collected from January 2018 to December 2020. We used an oncology-specific trigger tool to identify adverse events during anthracycline-based regimens. Independent variables were evaluated in univariate analysis: age, weight loss, marital status, total cumulative dose, polypharmacy, types of anthracyclines, and metastatic status. Bivariate and multivariate analyses were conducted to find out the relationship between the independent variables and adverse events.Results: In total, 107 subject records were collected and reviewed. Triggers were identified 122 times in 86 medical records. Blood transfusion, the most common trigger, was found in 35% of subjects. We found the number of triggers and adverse events more commonly identified in the first and second cycles of chemotherapy. The prevalence of adverse events is detected in 80% of subjects. Of these 86 subjects, 74% were detected in doxorubicin and 26% were detected in epirubicin. All the adverse events were categorized as The National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) harm category E.Conclusion: Trigger tools specific for cancer patients can be used to identify adverse events. Blood transfusion was the common trigger to detect adverse events in our study. Adverse events with category E were identified in all the subjects. Neutropenia and anemia were the most common adverse events in all cycles of chemotherapy. Weight loss was the independent variable related to adverse events in elderly breast cancer patients (p <0.003).","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79985950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Azmi Ritana, Dewi Aisiyah Mukarramah, M. Kiat, Kasih Rahardjo Djarot, Irena Sakura Rini, Resti Mulyasari, Oskar Ady Widarta
Introduction: Free tissue transfer performed in patients with hematologic malignancies has several considerable challenges. Studies that report the challenges and outcomes related to these patients have been rather limited. This study presents the outcome of free tissue transfer as the reconstructive option for patients with hematologic malignancies. This study reports our experience regarding the perioperative evaluation, management, and outcomes of five patients with hematological malignancies that underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia. Case Presentation: Five patients with hematologic malignancies, aged 26 to 60 years, who underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia from January 2017 to February 2020 were included. The outcomes such as flap survival, complications, and mortality were reviewed. There were three patients with NonHodgkin lymphoma (NHL), one patient with peripheral T-cell lymphoma, and one patient with acute myeloid leukemia (AML). All patients received free tissue transfer with flap modalities such as radial free forearm flap and anterolateral thigh. One patient had a postoperative complication of vein compromise and was treated with negative pressure wound therapy (NPWT), which resulted in partial flap necrosis. Dehiscence was also found in one patient, and the patient underwent reoperation. Then, a myocutaneous trapezius flap was applied. There was no total flap loss, no donor site morbidity, and no mortality. Conclusions: This study has shown that free tissue transfer was a reliable reconstructive option for patients with hematologic malignancies. Flap survival and minimal complications can be achieved by optimizing the patient’s condition preoperatively, performing the meticulous nontraumatic surgical technique, closely monitoring potential post-operative complications, and implementing a multidisciplinary approach with the hematooncologists.
{"title":"Free Tissue Transfer in Patients with Hematologic Malignancies: A Case Series","authors":"Azmi Ritana, Dewi Aisiyah Mukarramah, M. Kiat, Kasih Rahardjo Djarot, Irena Sakura Rini, Resti Mulyasari, Oskar Ady Widarta","doi":"10.33371/ijoc.v16i4.913","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.913","url":null,"abstract":"Introduction: Free tissue transfer performed in patients with hematologic malignancies has several considerable challenges. Studies that report the challenges and outcomes related to these patients have been rather limited. This study presents the outcome of free tissue transfer as the reconstructive option for patients with hematologic malignancies. This study reports our experience regarding the perioperative evaluation, management, and outcomes of five patients with hematological malignancies that underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia. Case Presentation: Five patients with hematologic malignancies, aged 26 to 60 years, who underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia from January 2017 to February 2020 were included. The outcomes such as flap survival, complications, and mortality were reviewed. There were three patients with NonHodgkin lymphoma (NHL), one patient with peripheral T-cell lymphoma, and one patient with acute myeloid leukemia (AML). All patients received free tissue transfer with flap modalities such as radial free forearm flap and anterolateral thigh. One patient had a postoperative complication of vein compromise and was treated with negative pressure wound therapy (NPWT), which resulted in partial flap necrosis. Dehiscence was also found in one patient, and the patient underwent reoperation. Then, a myocutaneous trapezius flap was applied. There was no total flap loss, no donor site morbidity, and no mortality. Conclusions: This study has shown that free tissue transfer was a reliable reconstructive option for patients with hematologic malignancies. Flap survival and minimal complications can be achieved by optimizing the patient’s condition preoperatively, performing the meticulous nontraumatic surgical technique, closely monitoring potential post-operative complications, and implementing a multidisciplinary approach with the hematooncologists.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86451046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yosafat Kurniawan Sugiarto, A. Singh, Muhammad Firdaus, Oskar Ady Widarta, Farilaila Rayhani
Introduction: Meningiomas are common and mostly benign intracranial tumors but may show a histological progression to malignancy. The mechanism of malignant transformation remains unclear. Malignant meningiomas usually bear a high recurrence rate and unfavorable prognosis; hence, multiple surgical resections are required for the treatmentCase Presentation: A 41-year-old woman with a prior history of craniotomy at another center six years ago with Meningioma Grade 1 presented to our institution with new neurological symptoms. The magnetic resonance image demonstrated a large frontal base mass that extended to the nasal cavity with diffuse contrast enhancement and extensive surrounding edema. A craniofacial approach combined with a bifrontal approach was performed in multistage tumor resection. The tumor and the infiltrated dura were radically removed. The histopathology demonstrated an Anaplastic Meningioma. The patient also underwent radiation therapy.Conclusion: Treatment of recurrent meningioma with anaplastic histology remains challenging because recurrence rates remain high with a poor prognosis.
{"title":"Resection of Anaplastic Meningioma via Combined Craniofacial Approach","authors":"Yosafat Kurniawan Sugiarto, A. Singh, Muhammad Firdaus, Oskar Ady Widarta, Farilaila Rayhani","doi":"10.33371/ijoc.v16i4.910","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.910","url":null,"abstract":"Introduction: Meningiomas are common and mostly benign intracranial tumors but may show a histological progression to malignancy. The mechanism of malignant transformation remains unclear. Malignant meningiomas usually bear a high recurrence rate and unfavorable prognosis; hence, multiple surgical resections are required for the treatmentCase Presentation: A 41-year-old woman with a prior history of craniotomy at another center six years ago with Meningioma Grade 1 presented to our institution with new neurological symptoms. The magnetic resonance image demonstrated a large frontal base mass that extended to the nasal cavity with diffuse contrast enhancement and extensive surrounding edema. A craniofacial approach combined with a bifrontal approach was performed in multistage tumor resection. The tumor and the infiltrated dura were radically removed. The histopathology demonstrated an Anaplastic Meningioma. The patient also underwent radiation therapy.Conclusion: Treatment of recurrent meningioma with anaplastic histology remains challenging because recurrence rates remain high with a poor prognosis.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77095283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dwirani Rosmala Pratiwi, D. Fauziah, Rizkie T Trisnawaty, Cindy Angelina Limantara
Introduction: Breast Fibromatosis is a rare benign stromal tumor that accounts for 0.2% of all breast tumors. The clinical presentation and imaging features may mimic a malignant tumor. We reported a case of breast fibromatosis mimicking breast cancer.Case Presentation: A 22-years-old woman with a palpable breast lump was present and being examined. The ultrasound and mammography features suggested malignancy. Magnetic Resonance Imaging (MRI) and Multislice Computerized Tomography (MSCT) evaluation showed invasion of a tumor to muscle without intrathoracic involvement. A core biopsy was performed with the pathologic conclusion suspected as a phyllodes tumor with a differential diagnosis as mammary fibromatosis. The pathology result of intraoperative examination favor for fibromatosis. A wide excision procedure with a free margin could be achieved. The histopathological examination revealed spindle cells tumor infiltrating into muscle tissue. The result of immunohistochemistry examination excluded metaplastic carcinoma and Phyllodes tumor. Therefore, it confirmed a diagnosis of breast fibromatosis.Conclusions: Breast fibromatosis is a rare benign tumor of the breast that can mimic malignancy. This entity should be considered as one of the differential diagnoses in a patient with a breast lump. A pre-operative tissue diagnostic is mandatory to prevent radical treatment for this nonmalignant case.
{"title":"A Case Report of Breast Fibromatosis Mimicking Breast Cancer","authors":"Dwirani Rosmala Pratiwi, D. Fauziah, Rizkie T Trisnawaty, Cindy Angelina Limantara","doi":"10.33371/ijoc.v16i4.919","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.919","url":null,"abstract":"Introduction: Breast Fibromatosis is a rare benign stromal tumor that accounts for 0.2% of all breast tumors. The clinical presentation and imaging features may mimic a malignant tumor. We reported a case of breast fibromatosis mimicking breast cancer.Case Presentation: A 22-years-old woman with a palpable breast lump was present and being examined. The ultrasound and mammography features suggested malignancy. Magnetic Resonance Imaging (MRI) and Multislice Computerized Tomography (MSCT) evaluation showed invasion of a tumor to muscle without intrathoracic involvement. A core biopsy was performed with the pathologic conclusion suspected as a phyllodes tumor with a differential diagnosis as mammary fibromatosis. The pathology result of intraoperative examination favor for fibromatosis. A wide excision procedure with a free margin could be achieved. The histopathological examination revealed spindle cells tumor infiltrating into muscle tissue. The result of immunohistochemistry examination excluded metaplastic carcinoma and Phyllodes tumor. Therefore, it confirmed a diagnosis of breast fibromatosis.Conclusions: Breast fibromatosis is a rare benign tumor of the breast that can mimic malignancy. This entity should be considered as one of the differential diagnoses in a patient with a breast lump. A pre-operative tissue diagnostic is mandatory to prevent radical treatment for this nonmalignant case.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80829376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: There is still a limited number of studies related to overall survival in breast cancer patients in Indonesia. This study determines the overall survival and the factor which can affect the survival of stage III breast cancer patients.Methods: This study was a retrospective study. Patients first diagnosed with stage III breast cancer from January 1 to August 31, 2018, at DR. Mohammad Hoesin General Hospital Palembang had been studied. The primary outcome of this study was overall survival. The sociodemographic, clinicopathology, and treatment factors were analyzed to identify the independent variables associated with overall survival using Kaplan-Meier and Cox proportional hazard regression.Results: In this study, 78 samples were included. The 3-year overall survival for stage III breast cancer was 71%. In the bivariate analysis, several factors including older age (> 40) (HR = 2.795, 95% CI 1.223–6.387), higher stages for IIIB (HR = 7.155, 95% CI 0.960–53.334), and IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354), history of not undergoing surgical intervention (HR = 3.999, 95% CI 1.684–9.495), and adjuvant chemotherapy (HR = 2.768, 95% CI 1.211–6.327) have been associated significantly to lower overall survival. Multivariate analysis showed IIIC breast cancer stage as an independent factor and had a significantly increased probability of mortality (HR = 14.677, 95% CI 1.268–169.948).Conclusions: The stage at diagnosis was the only significant predictor for the survival outcome, indicating that early diagnosis may need more attention.
背景:在印度尼西亚，与乳腺癌患者总生存率相关的研究仍然有限。本研究确定了III期乳腺癌患者的总生存期及影响生存期的因素。方法:本研究为回顾性研究。研究人员对2018年1月1日至8月31日在穆罕默德·胡辛综合医院(DR. Mohammad Hoesin General Hospital)首次诊断为III期乳腺癌的患者进行了研究。这项研究的主要终点是总生存期。使用Kaplan-Meier和Cox比例风险回归分析社会人口学、临床病理学和治疗因素，以确定与总生存率相关的自变量。结果:本研究共纳入78份样本。III期乳腺癌的3年总生存率为71%。在双变量分析中，包括年龄较大(> 40岁)(HR = 2.795, 95% CI 1.233 - 6.387)、IIIB分期较高(HR = 7.155, 95% CI 0.960-53.334)和IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354)、未接受手术干预史(HR = 3.999, 95% CI 1.684-9.495)和辅助化疗(HR = 2.768, 95% CI 1.211-6.327)在内的几个因素与总生存率降低显著相关。多因素分析显示，IIIC乳腺癌分期是一个独立因素，其死亡率显著增加(HR = 14.677, 95% CI 1.268 ~ 169.948)。结论:诊断阶段是唯一重要的生存预后指标，提示早期诊断可能需要更多的关注。
{"title":"Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors","authors":"Raehan Satya Deanasa Deanasa, Mulawan Umar, Agita Diora Fitri","doi":"10.33371/ijoc.v16i4.905","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.905","url":null,"abstract":"Background: There is still a limited number of studies related to overall survival in breast cancer patients in Indonesia. This study determines the overall survival and the factor which can affect the survival of stage III breast cancer patients.Methods: This study was a retrospective study. Patients first diagnosed with stage III breast cancer from January 1 to August 31, 2018, at DR. Mohammad Hoesin General Hospital Palembang had been studied. The primary outcome of this study was overall survival. The sociodemographic, clinicopathology, and treatment factors were analyzed to identify the independent variables associated with overall survival using Kaplan-Meier and Cox proportional hazard regression.Results: In this study, 78 samples were included. The 3-year overall survival for stage III breast cancer was 71%. In the bivariate analysis, several factors including older age (> 40) (HR = 2.795, 95% CI 1.223–6.387), higher stages for IIIB (HR = 7.155, 95% CI 0.960–53.334), and IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354), history of not undergoing surgical intervention (HR = 3.999, 95% CI 1.684–9.495), and adjuvant chemotherapy (HR = 2.768, 95% CI 1.211–6.327) have been associated significantly to lower overall survival. Multivariate analysis showed IIIC breast cancer stage as an independent factor and had a significantly increased probability of mortality (HR = 14.677, 95% CI 1.268–169.948).Conclusions: The stage at diagnosis was the only significant predictor for the survival outcome, indicating that early diagnosis may need more attention.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77855141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Lubis, Rafa Nabila Haifa, Rizky Yusfasari, Muhammad Zikri Agung Ramadhan
Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.
{"title":"Ventriculography Modality in Detection and Evaluation of Cardiotoxicity in Breast Cancer Patients Receiving Chemotherapy","authors":"H. Lubis, Rafa Nabila Haifa, Rizky Yusfasari, Muhammad Zikri Agung Ramadhan","doi":"10.33371/ijoc.v16i4.906","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.906","url":null,"abstract":"Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84557065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dwirani Rosmala Pratiwi, N. Syakdiyah, Ario Djatmiko, Lia Natalia Hinting
Introduction: Chemotherapy has been shown to reduce breast cancer (BC) mortality significantly. However, several types of chemotherapy drugs affect the reproductive system. As BC has become increasingly prevalent, many young women are diagnosed during their reproductive years. As a result, overcoming chemotherapy-related infertility is becoming increasingly important. Hence, in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy is considered a way to preserve future reproductive potential. For this reason, this paper aims to report the cases of safe pregnancy in BC survivors through pre-chemotherapy IVF followed by embryo cryopreservation.Case Presentation: Two women, aged 35 and 29, respectively, were treated for BC by surgery, chemotherapy, and tamoxifen. They performed in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy. Their pregnancy was completed without complications, and they gave birth to healthy babies. Their last oncological visit also showed no signs of cancer recurrence, showing disease-free intervals of seven and eight years, respectively.Conclusions: Pre-chemotherapy IVF followed by embryo cryopreservation can be an alternative to treat infertility in BC survivors of reproductive age who are receiving chemotherapy.
{"title":"Embryo Cryopreservation as an Alternative to Treat Infertility in Breast Cancer Survivors in Reproductive Age: Case Reports","authors":"Dwirani Rosmala Pratiwi, N. Syakdiyah, Ario Djatmiko, Lia Natalia Hinting","doi":"10.33371/ijoc.v16i4.935","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.935","url":null,"abstract":"Introduction: Chemotherapy has been shown to reduce breast cancer (BC) mortality significantly. However, several types of chemotherapy drugs affect the reproductive system. As BC has become increasingly prevalent, many young women are diagnosed during their reproductive years. As a result, overcoming chemotherapy-related infertility is becoming increasingly important. Hence, in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy is considered a way to preserve future reproductive potential. For this reason, this paper aims to report the cases of safe pregnancy in BC survivors through pre-chemotherapy IVF followed by embryo cryopreservation.Case Presentation: Two women, aged 35 and 29, respectively, were treated for BC by surgery, chemotherapy, and tamoxifen. They performed in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy. Their pregnancy was completed without complications, and they gave birth to healthy babies. Their last oncological visit also showed no signs of cancer recurrence, showing disease-free intervals of seven and eight years, respectively.Conclusions: Pre-chemotherapy IVF followed by embryo cryopreservation can be an alternative to treat infertility in BC survivors of reproductive age who are receiving chemotherapy.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73927733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Paskarani, Ni Gusti Ayu Agung Manik Yuniawaty Wetan, N. Sriwidyani, Sang Ayu Putu Yuliantini
Introduction: Metaplastic Breast Carcinoma (MBC) is quite a challenging case because metaplastic breast cancer is one of the rarest subtypes of invasive breast cancer. It is reported that MBC occurs only 0.2 to 1% throughout the world. The metaplastic changes can be squamous cells or other mesenchymal cell types. Clinically, MBC presents as a large palpable mass and may be associated with rapid growth. The size of MBC tends to be larger compared with other types of invasive breast cancer ranging from 1 to more than 10 cm. Although there are several main categories of MBC, some carcinoma can be difficult to classify due to their unusual histologic patterns. This case report study is to provide a clinicopathological overview and approach to MBC.Case Presentation: We reported a 49-year-old woman who suffered from a breast mass that rapidly grew for less than one year. The microscopic findings showed squamous cell carcinoma. While molecular studies revealed triple negative results for hormone receptors although Human Epidermal Growth Factor Receptor 2 (HER2) overexpression was unusual (< 5%). Then, we confirmed with chromogen in situ hybridization (CISH) and there was no gen amplification for HER2. Microscopically, we found ductal carcinoma in situ and this finding supported breast origin.Conclusions: Metaplastic carcinoma did not have any specific and distinctive signs clinically. Metaplastic carcinoma can be monophasic (with only a metaplastic component) or biphasic with two or more components. As treatment options, our patient received conventional chemotherapy. Metaplastic breast cancer is reported to have a lower response rate to conventional adjuvant chemotherapy and worse clinical outcome after chemotherapy than other forms of triple-negative breast cancer.
{"title":"Metaplastic Breast Carcinoma (MBC), Primary Squamous Cell Carcinoma Subtype in A 49-Year-Old Woman: A Case Report","authors":"P. Paskarani, Ni Gusti Ayu Agung Manik Yuniawaty Wetan, N. Sriwidyani, Sang Ayu Putu Yuliantini","doi":"10.33371/ijoc.v16i4.932","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.932","url":null,"abstract":"Introduction: Metaplastic Breast Carcinoma (MBC) is quite a challenging case because metaplastic breast cancer is one of the rarest subtypes of invasive breast cancer. It is reported that MBC occurs only 0.2 to 1% throughout the world. The metaplastic changes can be squamous cells or other mesenchymal cell types. Clinically, MBC presents as a large palpable mass and may be associated with rapid growth. The size of MBC tends to be larger compared with other types of invasive breast cancer ranging from 1 to more than 10 cm. Although there are several main categories of MBC, some carcinoma can be difficult to classify due to their unusual histologic patterns. This case report study is to provide a clinicopathological overview and approach to MBC.Case Presentation: We reported a 49-year-old woman who suffered from a breast mass that rapidly grew for less than one year. The microscopic findings showed squamous cell carcinoma. While molecular studies revealed triple negative results for hormone receptors although Human Epidermal Growth Factor Receptor 2 (HER2) overexpression was unusual (< 5%). Then, we confirmed with chromogen in situ hybridization (CISH) and there was no gen amplification for HER2. Microscopically, we found ductal carcinoma in situ and this finding supported breast origin.Conclusions: Metaplastic carcinoma did not have any specific and distinctive signs clinically. Metaplastic carcinoma can be monophasic (with only a metaplastic component) or biphasic with two or more components. As treatment options, our patient received conventional chemotherapy. Metaplastic breast cancer is reported to have a lower response rate to conventional adjuvant chemotherapy and worse clinical outcome after chemotherapy than other forms of triple-negative breast cancer.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"93 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74094107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atik Diah Mutiara Ningsih, Nur Qodir, A. Umar, Mulawan Umar, P. Suryani, Citra Dewi
Background: Breast cancer has had the highest mortality and morbidity globally in recent years. Breast cancer in young women presents with biological characteristics of more aggressive cancer, generally detected at advanced stage and a poorer prognosis. This study aimed to determine the characteristics of the incidence of breast cancer in young female patients at Dr. Mohammad Hoesin General Hospital Palembang in 2019–2020.Methods: This study is descriptive observational study conducted in October–November 2021. After having ethical approval from the Institutional Review Committee, research data were obtained from the medical records of young female patients diagnosed with breast cancer from January 1, 2019 to December 31, 2020. Samples were collected by using total sampling with the patient’s young age limit of fewer than 40 years.Results: The incidence of breast cancer was 20.9% (169 patients). The number of samples in this study was 120. Sociodemographic characteristics include the age range of 35–39 years around 63.3% (76 people), the highest education level of senior high school around 35% (42 people), not working around 73.3% (88 people), and living in the Palembang City area around 47.5% (57 people). Clinicopathological characteristics include the stage at the first diagnosis of stage IIIB about 46.7% (56 people), luminal B clinical subtype about 60% (72 people), and most histopathological type of invasive carcinoma of no special type about 88.3% (106 people).Conclusions: The incidence of breast cancer in young women is less than in older women but has worse cancer characteristics
{"title":"Characteristics of Breast Cancer in Young Female Patients in Dr. Mohammad Hoesin General Hospital Palembang","authors":"Atik Diah Mutiara Ningsih, Nur Qodir, A. Umar, Mulawan Umar, P. Suryani, Citra Dewi","doi":"10.33371/ijoc.v16i4.907","DOIUrl":"https://doi.org/10.33371/ijoc.v16i4.907","url":null,"abstract":"Background: Breast cancer has had the highest mortality and morbidity globally in recent years. Breast cancer in young women presents with biological characteristics of more aggressive cancer, generally detected at advanced stage and a poorer prognosis. This study aimed to determine the characteristics of the incidence of breast cancer in young female patients at Dr. Mohammad Hoesin General Hospital Palembang in 2019–2020.Methods: This study is descriptive observational study conducted in October–November 2021. After having ethical approval from the Institutional Review Committee, research data were obtained from the medical records of young female patients diagnosed with breast cancer from January 1, 2019 to December 31, 2020. Samples were collected by using total sampling with the patient’s young age limit of fewer than 40 years.Results: The incidence of breast cancer was 20.9% (169 patients). The number of samples in this study was 120. Sociodemographic characteristics include the age range of 35–39 years around 63.3% (76 people), the highest education level of senior high school around 35% (42 people), not working around 73.3% (88 people), and living in the Palembang City area around 47.5% (57 people). Clinicopathological characteristics include the stage at the first diagnosis of stage IIIB about 46.7% (56 people), luminal B clinical subtype about 60% (72 people), and most histopathological type of invasive carcinoma of no special type about 88.3% (106 people).Conclusions: The incidence of breast cancer in young women is less than in older women but has worse cancer characteristics","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"23 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72616898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：